Molnupiravir To Reach 105 LMICs Through MPP Agreement
Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral
Executive Summary
Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.
You may also be interested in...
MPP Strikes Long-Acting Injectable Cabotegravir Deal For HIV PrEP
After the Medicines Patent Pool secured a licensing deal with ViiV Healthcare for long-acting injectable cabotegravir for HIV pre-exposure prophylaxis, prospective generic sub-licensees have until 4 September to submit expressions of interest.
MPP Strikes Long-Acting Injectable Cabotegravir Deal For HIV PrEP
After the Medicines Patent Pool secured a licensing deal with Viiv Healthcare for long-acting injectable cabotegravir for HIV pre-exposure prophylaxis, prospective generic sub-licensees have until 4 September to submit expressions of interest.
MPP Announces Generic Paxlovid Licences For LMICs
A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.